Felicia Ladin - Albany Molecular CFO, Senior Vice President Treasurer
President
Ms. Felicia Ladin is Chief Financial Officer, Senior Vice President, Treasurer of Albany Molecular Research Inc., since February 4, 2015. Ms. Ladin brings more than 20 years of finance, accounting and tax management experience to AMRI. A CPA by training, Ms. Ladin has spent the majority of her career in the pharmaceutical industry, most recently as Senior Vice President, CFO, Global Specialty Medicines at Teva Pharmaceuticals Industries, Ltd. Between 2008 and 2014, Ms. Ladin held positions of increasing responsibility directing Tevas financial planning and analysis operations, and from 2002 to 2008 was tax director for the U.S. During her 12 year tenure at Teva, Ms. Ladin was instrumental in developing and implementing financial systems and infrastructure through a number of acquisitions, and driving consistency and efficiencies across locations, supporting the Specialty Medicine divisions growth into an 8 billion global business since 2015.
| Age | 42 |
| Tenure | 9 years |
| Phone | 518 512-2000 |
| Web | www.amriglobal.com |
Albany Molecular Management Efficiency
The company has return on total asset (ROA) of (0.0657) % which means that it has lost $0.0657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.1137) %, meaning that it created substantial loss on money invested by shareholders. Albany Molecular's management efficiency ratios could be used to measure how well Albany Molecular manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 647.96 M in liabilities with Debt to Equity (D/E) ratio of 204.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Albany Molecular Research has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Albany Molecular until it has trouble settling it off, either with new capital or with free cash flow. So, Albany Molecular's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Albany Molecular Research sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Albany to invest in growth at high rates of return. When we think about Albany Molecular's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 13 records | PRESIDENT Age | ||
| Gerard Versteegh | SunOpta | 54 | |
| Steve Thompson | Boyd Gaming | 55 | |
| Jill Barnett | SunOpta | 50 | |
| Theodore Bogich | Boyd Gaming | 68 | |
| Josh Hirsberg | Boyd Gaming | 62 | |
| Brian Larson | Boyd Gaming | 62 | |
| Marianne Johnson | Boyd Gaming | 66 | |
| Stephen Thompson | Boyd Gaming | 64 | |
| Lillian Barlett | SunOpta | 53 | |
| Ted Bogich | Boyd Gaming | N/A | |
| Anthony McDuffie | Boyd Gaming | 59 | |
| James Gratzek | SunOpta | 51 | |
| Craig Abrahams | Playtika Holding Corp | 47 | |
Management Performance
| Return On Equity | -22.11 | |||
| Return On Asset | -0.0657 |
Albany Molecular Research Leadership Team
Elected by the shareholders, the Albany Molecular's board of directors comprises two types of representatives: Albany Molecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Albany. The board's role is to monitor Albany Molecular's management team and ensure that shareholders' interests are well served. Albany Molecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Albany Molecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Svokos, COO | ||
| Arthur Roth, Independent Director | ||
| Gerardo Gutierrez, Director | ||
| Thomas Ambra, Non-Executive Chairman of the Board | ||
| Lori Henderson, Vice President General Counsel, Secretary | ||
| Milton Boyer, Senior Vice President - Drug Product Manufacturing | ||
| Anthony Maddaluna, Director | ||
| Kenneth Hagen, Director | ||
| Fernando Napolitano, Director | ||
| Una Ryan, Lead Independent Director | ||
| David Deming, Director | ||
| Kevin Connor, Independent Director | ||
| Jimmy Wang, CIO | ||
| Gabriel Leung, Independent Director | ||
| Steven Hagen, Sr. VP of Manufacturing, Pharmaceuticals and Operations | ||
| Christopher Conway, Senior Vice President - Global Sales and Marketing | ||
| Felicia Ladin, CFO, Senior Vice President Treasurer | ||
| Veronica Jordan, Independent Director | ||
| William Marth, CEO and President and Director |
Albany Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Albany Molecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.11 | |||
| Return On Asset | -0.0657 | |||
| Profit Margin | (11.94) % | |||
| Operating Margin | 0.87 % | |||
| Current Valuation | 981.79 M | |||
| Shares Outstanding | 42.7 M | |||
| Shares Owned By Insiders | 15.91 % | |||
| Shares Owned By Institutions | 97.30 % | |||
| Number Of Shares Shorted | 5.61 M | |||
| Price To Earning | (15.32) X |
Pair Trading with Albany Molecular
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albany Molecular position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albany Molecular will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Teradata Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Teradata Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Teradata Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Teradata Corp to buy it.
The correlation of Teradata Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Teradata Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Teradata Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Teradata Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Albany Stock
If you are still planning to invest in Albany Molecular Research check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albany Molecular's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |